WilliamHLiggettMD

PubMed

• 5 citations
  A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
  Denise A. Yardley, William Liggett, Mark Mainwaring, Aurelio Castrellon, Laura Blakely, Brian Hemphill, Bertrand Anz, Robyn R. Young, Mythili Shastry, Laura M. DeBusk,...> ;Clinical Breast Cancer. 2020 Apr 1
• Phase II pilot trial of imatinib mesylate with weekly docetaxel in metastatic breast cancer.
  Barton JH, Liggett W, Mainwaring M, Hainsworth JD, Simons L, Spigel DR, Burris Iii HA, Yardley DA> ;J. Clin. Oncol.. 2006-06-20
• Topotecan-Single agent activity in a weekly intravenous (IV) schedule for first-line therapy in poor prognosis extensive stage small cell lung cancer (SCLC): A Minnie ...
  Murphy PB, Hainsworth JD, Spigel DR, Gray JR, Liggett WH, Shipley DL, Switzer A, Gandhi JG, Dannaher CL, Greco FA> ;J. Clin. Oncol.. 2006-06-20
• Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by maintenance bevacizumab (B) in the treatment (tx) of limited-stage small cell lung cancer (LS-SCLC):...
  Patton JF, Spigel DR, Greco FA, Liggett WH, Zubkus JD, Baskette M, Schreeder M, Woytowitz D, Nelson E, Hainsworth JD> ;J. Clin. Oncol.. 2006-06-20
• Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by bevacizumab (B) in the treatment of limited-stage small cell lung cancer (SCLC): A phase II trial of...
  Raefsky EL, Spigel DR, Greco FA, Yardley DA, Bradof JE, Woytowitz DV, Schreeder MT, Liggett WH, Zubkus JD, Petrone D, Hainsworth JD> ;J. Clin. Oncol.. 2005-06-01
• Fludarabine/rituximab (FR) followed by alemtuzumab as first-line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL): A ...
  Liggett WH, Hainsworth JD, Spigel DR, Meluch AA, Raefsky EL, Kennedy S, Thomas M, Grimaldi M, Saez RA, Greco FA> ;J. Clin. Oncol.. 2005-06-01
• 272 citations
  Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy
  Stephen T. Sonis, June P. Eilers, Joel B. Epstein, Francis G. LeVeque, William H. Liggett, Mary T. Mulagha, Douglas E. Peterson, Ann H. Rose, Mark M. Schubert, Frederi...> ;Cancer. 1999 May 15
• 66 citations
  p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer.
  James W. Rocco, Daqing Li, William H. Liggett, Ling Duan, John K. Saunders, David Sidransky, Bert W. O'Malley> ;Clinical Cancer Research. 1998 Jul 1
• 514 citations
  Role of the p16 tumor suppressor gene in cancer.
  William H. Liggett, David Sidransky> ;Journal of Clinical Oncology. 1998 Mar 1
• 86 citations
  p16 and p16β Are Potent Growth Suppressors of Head and Neck Squamous Carcinoma Cells in Vitro
  William H. Liggett, Duane Sewell, James W. Rocco, Steven A. Ahrendt, Wayne M. Koch, David Sidransky> ;Cancer Research. 1996 Sep 15
• 11 citations
  Chemotherapy advances in head and neck oncology.
  William H. Liggett, Arlene A. Forastiere> ;Seminars in Surgical Oncology. 1995 May 1
• 34 citations
  Osteocalcin promotes differentiation of osteoclast progenitors from murine long-term bone marrow cultures.
  William H. Liggett, Jane B. Lian, Joel S. Greenberger, Julie Glowacki> ;Journal of Cellular Biochemistry. 1994 Jun 1
• Join now to see all